GERON CORP

GERNNASDAQ

🏆 #2275 by market capEarnings Nov 4US Equity

$1.61▼ $0.02 (−1.23%)

Live

1h▼ 1.5%

24h▼ 1.2%

7d▼ 0.9%

14d▲ 14.2%

30d▲ 13.8%

1y▲ 19.7%

🏦Market Cap

$1.03B

Small Cap

📈Revenue Growth (YoY)

+138.8%

High Growth

📊Gross Margin

83.2%

High

💵FCF Margin

-56.1%

Thin

⚖️P/S Ratio

5.0x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $1.60 – $1.64
52-Week Range: $1.04 – $2.01
Volume: $2.22B
Avg Volume: $1.54B
Shares Outstanding: 641.5M
Next Earnings: Oct 14, 2026

Fundamentals Snapshot

Annual Revenue: $184M
Last Q Revenue: $57M
P/E Ratio: -16.1
P/S Ratio: 5.0x
EPS (TTM): $-0.10
Dividend Yield: 0.00%

Why Investors Own GERN

✓High-growth profile — revenue up +10.0% YoY with expanding US Equity exposure.
✓Healthy economics — 68% gross margin and 26% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$184M▲ +12.9% YoY

Gross Margin (TTM)

68.4%▼ −0.5% YoY

Operating Income (TTM)

$44M▲ +12.9% YoY

Free Cash Flow (TTM)

$47M▲ +12.9% YoY

About GERON CORP

Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.

🦦